Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Pulse Biosciences ( (PLSE) ) is now available.
Pulse Biosciences announced the appointment of Paul A. LaViolette as Chief Executive Officer and President, effective January 9, 2025. Mr. LaViolette, who has extensive experience in the healthcare and medical technology sectors, will also act as the principal executive and financial officer. This appointment comes with an at-will Employment Agreement, including stock options contingent on performance milestones. The announcement signals a strategic move to leverage Mr. LaViolette’s expertise to enhance the company’s positioning in the medical technology industry, particularly in its innovative nano-PFA technology development and market expansion efforts.
More about Pulse Biosciences
Pulse Biosciences is a bioelectric medicine company focused on health innovation, headquartered in Miami, Florida. The company specializes in its proprietary CellFX nsPFA technology, which uses nanosecond pulses of electrical energy for medical treatments, particularly in atrial fibrillation and other select markets, aiming to improve healthcare outcomes.
YTD Price Performance: 3.79%
Average Trading Volume: 168,109
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.14B
For an in-depth examination of PLSE stock, go to TipRanks’ Stock Analysis page.
